Search results for "Opiate Substitution Treatment"

showing 9 items of 9 documents

Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence

2014

Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs). Increasing the range of therapeutic options optimizes outcomes and facilitates patient management. An international, multi-center, two-phase study investigated the efficacy and safety of slow-release oral morphine (SROM) versus methadone in patients receiving methadone therapy for opioid dependence. In phase 1 (two way cross-over, 11 weeks each period) patients were randomized to SROM or methadone oral solution. In phase 2 (25 weeks), patients continued treatment with SROM (group A) or switched from methadone to SROM (group B). In total, 211 out of 276 completed phase 1 and 198 entered phase 2 …

AdultMaleInternational CooperationAdministration OralMedicine (miscellaneous)QT intervalHeroinOpiate Substitution TreatmentHumansMedicineIn patientOral morphineAdverse effectCross-Over StudiesMorphinebusiness.industryOpioid-Related DisordersEuropePsychiatry and Mental healthClinical PsychologyTreatment OutcomeOpioidTolerabilityDelayed-Action PreparationsAnesthesiaFemalePshychiatric Mental HealthbusinessMethadonemedicine.drugMethadoneJournal of Substance Abuse Treatment
researchProduct

Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone

2012

Aims To compare the efficacy of slow-release oral morphine (SROM) and methadone as maintenance medication for opioid dependence in patients previously treated with methadone. Design Prospective, multiple-dose, open label, randomized, non-inferiority, cross-over study over two 11-week periods. Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment. Setting Fourteen out-patient addiction treatment centres in Switzerland and Germany. Participants Adults with opioid dependence in methadone maintenance programmes (dose ≥50 mg/day) for ≥26 weeks. Measurements The efficacy end-point was the proportion of heroin-positive urine samp…

AdultMaleNarcoticsMethadone maintenanceretention ratePopulationslow-release oral morphineAdministration OralMedicine (miscellaneous)Maintenance ChemotherapyMedication AdherencemethadoneOpiate Substitution TreatmentmedicineHumanseducationMorphine Derivativeseducation.field_of_studyCross-Over StudiesMorphinemaintenance treatmentCodeinebusiness.industryCodeineResearch ReportsOpioid use disorderOpiate Substitution TreatmentMiddle AgedOpioid-Related Disordersmedicine.diseaseCrossover studyPsychiatry and Mental healthTreatment OutcomeOpioidDelayed-Action PreparationsAnesthesiaFemaleDose–responsebusinessopioid addictionMethadonemedicine.drugAddiction
researchProduct

Exercise as an Adjuvant Intervention in Opiate Dependence

2013

We read with interest the article by Weinstock et al. in whichthe authors propose exercise as an adjuvant intervention inopiate agonist treatment based on current research findings(1).The use of an opiate agonist, such as buprenorphine, butmainly, methadone, for the treatment of opiate dependenceis currently an effective therapy for this type of addiction.The main benefits of this treatment occur through a relieffrom craving narcotic drugs, a temporally suppression ofwithdrawal symptoms, and by blocking the euphoric effectsof opiates (2). Unfortunately, patients needing treatment foropiatedependenceoftenfaceavarietyofco-occurringissues,suchashepatitisBandCvirusesorhumanimmunodeficiencyvirus (H…

Agonistmedicine.medical_specialtymedicine.drug_classmedia_common.quotation_subjectMedicine (miscellaneous)CravingBioinformaticsHeroinOpiate Substitution TreatmentmedicineHumansPsychiatrymedia_commonbusiness.industryAddictionOpioid-Related Disordersmedicine.diseaseCombined Modality TherapyExercise TherapySubstance abusePsychiatry and Mental healthmedicine.symptomOpiatebusinessMethadonemedicine.drugBuprenorphineSubstance Abuse
researchProduct

From political controversy to a technical problem? Fifteen years of opioid substitution treatment in Finland

2013

Abstract Background The aim of the article is to analyze changes in opioid substitution treatments (OST) in Finland. OST spread in Finland in the late 1990s and early 2000s (Phase 1). Since then, OST has become an integrated part of Finnish drug policy and is provided in various substance abuse treatment units as well as in municipal health centers (Phase 2). Methods The paper analyses the policy around the implementation of opioid substitution treatment in Finland, focusing on identifying the key factors and the relations between them that have contributed to the implementation of OST in Finland. Results OST has become accepted in Finland during the past ten years as a crucial element of a…

Economic growthTime FactorsRestructuringMedicine (miscellaneous)Poison controlSuicide preventionHeroinDrug UsersHarm ReductionHealth careOpiate Substitution TreatmentHumansMedicineCommunity Health ServicesPolicy MakingFinlandHarm reductionHeroin Dependencebusiness.industryHealth PolicyPoliticsfungiAnalgesics OpioidTreatment OutcomeIncentivePsychological DistancePublic Opinionta5141Government RegulationDrug and Narcotic ControlSubstance Abuse Treatment Centersbusinessmedicine.drugBuprenorphineInternational Journal of Drug Policy
researchProduct

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

2021

International audience; Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-re…

MaleNarcotic Antagonists[SDV]Life Sciences [q-bio]ToxicologyMESH: Analgesics Opioid0302 clinical medicineInterquartile rangeSurveys and QuestionnairesPharmacology (medical)030212 general & internal medicineSurveymedia_commonMESH: Patient PreferenceMESH: Middle AgedOpioid use disorderPatient PreferenceMiddle AgedBuprenorphineAnalgesics OpioidPsychiatry and Mental healthMESH: Young AdultFemaleFranceMESH: Narcotic AntagonistsPatients' preferencemedicine.drugAdultmedicine.medical_specialtyAdolescentMESH: Delayed-Action Preparationsmedia_common.quotation_subjectMESH: BuprenorphineMESH: Opiate Substitution TreatmentInjections03 medical and health sciencesYoung AdultInternal medicinemedicineOpiate Substitution TreatmentHumansMESH: InjectionsDosingMESH: Surveys and QuestionnairesPharmacologyMESH: AdolescentMESH: Humansbusiness.industryMESH: AdultOdds ratioAbstinencemedicine.diseaseOpioid-Related DisordersConfidence intervalMESH: MaleMESH: Opioid-Related DisordersMESH: FranceDelayed-Action PreparationsMESH: MethadoneExtended-releasebusinessMESH: Female030217 neurology & neurosurgeryMethadoneMethadoneBuprenorphine
researchProduct

Changes of QTc interval after opioid switching to oral methadone.

2013

Abstract A consecutive sample of patients who were switched from strong opioids to methadone in a period of 1 year was surveyed. QTc was assessed before switching (T0) and after achieving adequate analgesia and an acceptable level of adverse effects (Ts). Twenty-eight of 33 patients were switched to methadone successfully. The mean initial methadone doses at T0 were 67.1 mg/day (SD ±80.2, range 12-390). The mean QTc interval at T0 was 400 ms (SD ±30, range 330-450). The mean QTc interval at Ts (median 5 days) was 430 ms (SD ±26, range 390-500). The difference (7.7 %) was significant (p < 0.0005). Only two patients had a QTc of 500 ms. No serious arrhythmia was observed. At the linear regres…

MaleRiskCancer pain; Methadone; QT prolongation; Toxicity; Opioid switchingPainSettore MED/41 - AnestesiologiaQT prolongationSettore MED/42 - Igiene Generale E ApplicataQT intervalCONSECUTIVE SAMPLEElectrocardiographyNeoplasmsOpiate Substitution TreatmentmedicineHumansIn patientcardiovascular diseasesCancer painAdverse effectAgedToxicitybusiness.industryMiddle AgedAnalgesics OpioidLong QT SyndromeOncologyOpioidAnesthesiaToxicityLinear Modelscardiovascular systemOpioid switchingFemaleCancer painbusinessMethadoneMethadonemedicine.drug
researchProduct

Slow release oral morphine versus methadone for the treatment of opioid use disorder

2019

ObjectiveTo assess the efficacy of slow release oral morphine (SROM) as a treatment for opioid use disorder (OUD).DesignSystematic review and meta-analysis of randomised controlled trials (RCTs).Data sourcesThree electronic databases were searched through 1 May 2018: the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We also searched the following electronic registers for ongoing trials: ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Current Controlled Trials and the EU Clinical Trials Register.Eligibility criteria for selecting studiesWe included RCTs of all durations, assessing the effect of SROM on measures of treatment retention, heroin use…

Narcoticsmedicine.medical_specialtyAddictionAdministration OralCraving1681substance use treatmentHeroin03 medical and health sciences0302 clinical medicineSlow release oral morphine (SROM)Internal medicineOpiate Substitution TreatmentHumansMedicine1506030212 general & internal medicine10. No inequalityAdverse effectRandomized Controlled Trials as TopicMorphinebusiness.industryResearchsubstance misuseopioid use disorderOpioid use disorderGeneral MedicineOpioid-Related Disordersmedicine.disease3. Good healthmeta-analysisClinical trialoral morphineOpioid use disorderReducing heroin useDelayed-Action PreparationsMeta-analysisRelative riskmedicine.symptombusinessMethadone030217 neurology & neurosurgerymedicine.drugMethadoneBMJ Open
researchProduct

Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?

2014

The aim of this review was to update and summarize the scientific knowledge on the long term outcomes of the different pharmacological treatment options for opioid dependence currently available and to provide a critical discussion on the different treatment options based on these results. We performed a literature search using the PubMed databases and the reference lists of the identified articles. Data from research show that the three pharmacological options reviewed are effective treatments for opioid dependence with positive long term outcomes. However, each one has its specific target population and setting. While methadone and buprenorphine are first line options, heroin-assisted tre…

Pharmacologymedicine.medical_specialtybusiness.industryTreatment optionsOpiate Substitution TreatmentHeroinHeroin-assisted treatmentOpioidmedicineLong term outcomesPharmacology (medical)businessPsychiatrymedicine.drugMethadoneBuprenorphineBritish Journal of Clinical Pharmacology
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct